(Q63816110)
Statements
An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra® (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Atopic Dermatitis (English)
0 references
November 2010
0 references
July 2011
0 references
100
0 references
6 month
0 references
11 year
0 references